News | Cath Lab | April 03, 2017

Study Examines Influence of Cardiac Arrest and Cardiogenic Shock on STEMI Patient Outcomes

Minneapolis Heart Institute Foundation study finds that presence of cardiac arrest and/or cardiogenic shock is responsible for more than 75 percent of hospital deaths in STEMI patients

STEMI, cardiac arrest, cardiogenic shock, ACC.17 study, Minneapolis Heart Institute Foundation, MHIF

April 3, 2017 — The influence of cardiac arrest and cardiogenic shock on outcomes of patients with ST-elevation myocardial infarction (STEMI) has not been completely studied. Researchers at the Minneapolis Heart Institute Foundation (MHIF) conducted a study to determine the incidence, characteristics and outcomes of STEMI complicated by cardiac arrest with or without cardiogenic shock.

Prospective data from the Level I regional STEMI program at the Minneapolis Heart Institute at Abbott Northwestern Hospital was examined from March 2003 to December 2014. Researchers analyzed STEMI patients who had cardiac arrest prior to any intervention. They specifically sought to determine how the type of cardiac arrest (shockable versus non-shockable rhythm) and the presence of cardiogenic shock affect patient outcomes.

MHIF researchers, led by Benjamin Johnson, M.D., enrolled 4,511 patients in this study. The incidence of cardiac arrest prior to intervention was 11 percent. In-hospital death occurred in 250 (6 percent) of patients. Cardiac arrest was present in 56 percent and cardiogenic shock in 53 percent of these patients. In patients with shockable cardiac arrest, in-hospital mortality was 2.8x higher if they had cardiogenic shock as compared to no cardiogenic shock. In patients with non-shockable cardiac arrest, in-hospital mortality was equally high regardless of the presence of cardiogenic shock. Among this 4,511-patient cohort, cardiac arrest and/or cardiogenic shock accounted for 76 percent of all hospital deaths. 

Johnson noted, “Cardiac arrest and cardiogenic shock are associated with significantly increased morbidity and mortality in patients presenting with ST elevation myocardial infarction. Efforts need to be made to better understand this population of patients presenting with STEMI complicated by cardiac arrest with or without cardiogenic shock.”

Results of the study were presented at the American College of Cardiology Annual Scientific Session & Expo (ACC.17), March 17-19 in Washington, D.C.

Read about another cariogenic shock study presented at ACC.17., “New Protocol at Henry Ford Hospital Dramatically Increases Heart Attack Survival Rates.”

Watch the VIDEO "VIDEO: Cardiogenic Shock Supported With Impella Shows Good Outcomes."

For more information: www.mplsheart.org

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init